Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.77 |
| ▸ | XDH | P47989 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
| ▸ | GFER | P55789 | 1/20 | 0.77 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.77 |
| ▸ | RELA | Q04206 | 1/20 | 0.77 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | CNR2 | P34972 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26395230 | 0.90 | POLB (0.62) | LMNAKDM4ETDP1XDHPOLB | |
| SCHEMBL26395222 | 0.90 | POLB (0.62) | LMNAKDM4ETDP1XDHPOLB | |
| SCHEMBL26395212 | 0.90 | POLB (0.62) | LMNAKDM4ETDP1XDHPOLB | |
| SCHEMBL198717 | 0.90 | KDM4E (0.65) | LMNAKDM4ETDP1XDHPOLB | |
| Gallic Acid Methyl Ester SCHEMBL39513 | 0.87 | KDM4E (1.00) | LMNAKDM4ETDP1XDHPOLB | |
| Gallic Acid Methyl Ester SCHEMBL28507408 | 0.85 | KDM4E (0.95) | LMNAKDM4ETDP1XDHPOLB | |
| Gallic Acid Methyl Ester SCHEMBL21611341 | 0.85 | KDM4E (0.95) | LMNAKDM4ETDP1XDHPOLB | |
| Gallic Acid Methyl Ester SCHEMBL21543905 | 0.85 | KDM4E (0.95) | LMNAKDM4ETDP1XDHPOLB | |
| Gallic Acid Methyl Ester SCHEMBL28556619 | 0.85 | KDM4E (0.95) | LMNAKDM4ETDP1XDHPOLB | |
| SCHEMBL31395255 | 0.85 | KDM4E (0.60) | LMNAKDM4ETDP1XDHPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111630051-B | Olefin spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11793823-B2 | Compounds and pharmaceutical uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-10-24 | — | — | US | disclosed |
| US-11779561-B2 | Compounds and pharmaceutical uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-10-10 | — | — | US | disclosed |
| US-20230241675-A1 | COMPOSITIONS, COMPRISING PLATELET-SHAPED TRANSITION METAL PARTICLES | BASF SE (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20210041425-A1 | COMPLEX LIQUID CRYSTAL DROPLETS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-02-11 | — | — | US | disclosed |
| US-20120277460-A1 | Fluorous Dendrimers and Methods for Production Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277460-A1 | Fluorous Dendrimers and Methods for Production Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-11-01 | — | — | US | disclosed |
| US-7696195-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277460-A1 | Fluorous Dendrimers and Methods for Production Thereof | CD69, FLT3, MYD88 | LMNA 3528/4885KDM4E 3782/4885TDP1 1610/4885 |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | LMNA 737/4885KDM4E 4579/4885TDP1 1580/4885 |
| US-11779561-B2 | Compounds and pharmaceutical uses thereof | ACE, ACE2, FURIN | LMNA 2707/4885KDM4E 4466/4885TDP1 3727/4885 |
| US-11793823-B2 | Compounds and pharmaceutical uses thereof | HRH4, OR10J3, CYP3A5 | LMNA 4372/4885KDM4E 2317/4885TDP1 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.